Home > News > Recent Updates in Inflammatory Ocular Diseases
Anterior Segment, Ocular Surface Disease
Read Time: 2 mins

Recent Updates in Inflammatory Ocular Diseases

Published Online: March 26th 2018 US Ophthalmic Review, 2018;11(1):19–20 DOI: https://doi.org/10.17925/USOR.2018.11.1.19
Authors: Bennie H Jeng
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Inflammatory ocular diseases cover a wide spectrum of conditions and are a growing public health concern. Dry eye disease is one of the most common conditions seen by eye care practitioners. Allergic conjunctivitis is also a highly prevalent condition, especially during hay fever season. In addition to these well characterized disorders, less-common inflammatory conditions such as Sjögren’s syndrome and Stevens-Johnson syndrome also affect the eyes. Early diagnosis of these conditions is essential to optimize outcomes. In an expert interview, Bennie Jeng, Professor and Chair of the Department of Ophthalmology and Visual Sciences at the University of Maryland School of Medicine, discusses some of the latest advances in the diagnosis and treatment of inflammatory eye disorders.

Keywords

Inflammatory ocular disease, MMP-9, tear
osmolarity, lactoferrin, Sjögren’s syndrome,
Stevens-Johnson syndrome, allergic conjunctivitis

Article:

Inflammatory ocular diseases cover a wide spectrum of conditions and are a growing public health concern. Dry eye disease is one of the most common conditions seen by eye care practitioners. Allergic conjunctivitis is also a highly prevalent condition, especially during hay fever season. In addition to these well characterized disorders, less-common inflammatory conditions such as Sjögren’s syndrome and Stevens-Johnson syndrome also affect the eyes. Early diagnosis of these conditions is essential to optimize outcomes. In an expert interview, Bennie Jeng, Professor and Chair of the Department of Ophthalmology and Visual Sciences at the University of Maryland School of Medicine, discusses some of the latest advances in the diagnosis and treatment of inflammatory eye disorders.

Q. What are the benefits and limitations of the MMP-9 test for
dry eye?

This point-of-care test detects the presence of matrix metalloproteinase 9 (MMP-9), an inflammatory marker that has been shown to be associated with dry eyes. Studies have demonstrated good sensitivity and excellent specificity. This test is easy and quick to do in the office, but it cannot quantitate the levels of MMP-9 to allow for tracking of improvement in dry eyes. As such, this test could be a useful adjunct when the diagnosis is in question.

Q. What other new point-of-care tests appear promising in dry eye?

Other point-of-care tests include tear osmolarity and lactoferrin. Like the MMP-9 test, these other tests are also quick to do in the office, but are best used as adjuncts to careful examination of the ocular surface for staining and tear break up times. Osmolarity levels can be used to track improvement over time, allowing demonstration to the patients of an objective metric.

Q. Could you tell us a little about the Sjö kit for early detection of Sjögren’s syndrome?

The Sjö kit has been introduced as a method for early detection of Sjögren’s syndrome. In addition to four traditional biomarkers, this kit also tests for three novel proprietary markers. With these new markers, the hope is that a diagnosis can be made sooner, thus allowing for earlier institution of therapy.

Q. What have been the most exciting recent developments in the diagnosis and treatment of allergic conjunctivitis?

There have been a number of newer therapies introduced that hold excellent promise for treating allergic conjunctivitis including sublingual immunotherapy (SLIT) and topical cetirizine. In addition, there are four new Food and Drug Administration (FDA)-approved products: Oralair® (sweet vernal, orchard, perennial rye, timothy and Kentucky bluegrass mixed pollens allergen extract), Grastek® (timothy grass pollen allergen extract), Ragwitek® (short ragweed pollen allergen extract), and Odactra™ (house dust mite allergen extract).

Q. What are the advantages of scleral lenses in patients with severe ocular disease such as Stevens-Johnson syndrome?

Scleral lenses have recently become very popular for treating severe ocular surface diseases. This patient population does not respond adequately to standard medical treatments with tear supplements, and even autologous serum. Scleral lenses offer another medical option to avoid a surgical procedure such as amniotic membrane grafting or tarsorrhaphy. In addition, scleral lenses have the added advantage of improving quality of vision in addition to relief of symptoms.

Article Information:
Disclosure

Bennie H Jeng has nothing to disclose in relation to this article.
Review Process : This is an expert interview with an
Editorial Board member and as such did not undergo the
journal’s standard peer review procedure.
Authorship : All named authors meet the International
Committee of Medical Journal Editors (ICMJE) criteria
for authorship of this manuscript, take responsibility
for the integrity of the work as a whole, and have
given final approval to the version to be published.

Correspondence

Bennie H Jeng,
Department of Ophthalmology and Visual Sciences,
419 West Redwood St, Suite 470, Baltimore, MD
21201, US. E: bjeng@som.umaryland.edu

Support

No funding was received in
the publication of this article.

Access

This article is published under the Creative
Commons Attribution Noncommercial License, which
permits any noncommercial use, distribution, adaptation,
and reproduction provided the original author(s) and
source are given appropriate credit. © The Authors 2018.

Received

2018-03-19T00:00:00

Further Resources

Share this Article
Related Content In Ocular Surface Disease
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72